-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the CDE official website showed that Hunan Hengsheng Pharmaceutical was accepted for its milrinone injection, which was reported to be a generic type 3 product
.
According to data from Minet.
com, the sales of milrinone injection in public medical institutions in China will exceed 900 million yuan in 2020, with a year-on-year increase of 0.
77% in the first half of 2021
.
This product has 15 companies with production approvals, of which 8 have been reviewed
.
Four companies including Sichuan Huiyu Pharmaceutical Co.
, Ltd.
and China Resources Sanjiu (Ya'an) Pharmaceutical Co.
, Ltd.
are under review for production under the new classification, and they will be deemed to have been reviewed after approval
.
.
According to data from Minet.
com, the sales of milrinone injection in public medical institutions in China will exceed 900 million yuan in 2020, with a year-on-year increase of 0.
77% in the first half of 2021
.
This product has 15 companies with production approvals, of which 8 have been reviewed
.
Four companies including Sichuan Huiyu Pharmaceutical Co.
, Ltd.
and China Resources Sanjiu (Ya'an) Pharmaceutical Co.
, Ltd.
are under review for production under the new classification, and they will be deemed to have been reviewed after approval
.
Milrinone injection was developed by Sanofi-Aventis.
It is a phosphodiesterase inhibitor class of cardiotonic drugs.
It has the effect of dilating vascular smooth muscle, reducing the load on the heart and improving blood supply to the kidneys and muscles.
, clinically used for short-term intravenous therapy in patients with acute decompensated heart failure
.
It is a phosphodiesterase inhibitor class of cardiotonic drugs.
It has the effect of dilating vascular smooth muscle, reducing the load on the heart and improving blood supply to the kidneys and muscles.
, clinically used for short-term intravenous therapy in patients with acute decompensated heart failure
.
According to data from Minet.
com, in 2020, the sales of terminal milrinone injection in China's urban public medical care, county-level public hospitals , urban community centers and township health centers (referred to as Chinese public medical institutions) will exceed 900 million yuan, and the first half of 2021 will increase year-on-year.
0.
77%
.
com, in 2020, the sales of terminal milrinone injection in China's urban public medical care, county-level public hospitals , urban community centers and township health centers (referred to as Chinese public medical institutions) will exceed 900 million yuan, and the first half of 2021 will increase year-on-year.
0.
77%
.
Review of Milrinone Injection
Source: One-click retrieval from Minet
Milrinone injection has 15 companies with production approvals, of which 8 have been reviewed.
Over-evaluation, Nanjing Jianyou Biochemical Pharmaceutical and Shanghai Xudong Haipu Pharmaceutical Co.
, Ltd.
were approved for production of 4 types of imitations, which are regarded as over-evaluation
.
Over-evaluation, Nanjing Jianyou Biochemical Pharmaceutical and Shanghai Xudong Haipu Pharmaceutical Co.
, Ltd.
were approved for production of 4 types of imitations, which are regarded as over-evaluation
.
Milrinone injection is under review
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
In addition, four pharmaceutical companies, including Sichuan Huiyu Pharmaceutical and China Resources Sanjiu (Ya'an) Pharmaceutical, are under review for production under the new classification, and will be deemed to have been reviewed after approval
.
It is worth mentioning that Milrinone injection is in the list of the seventh batch of planned centralized procurement.
Minet will continue to pay attention to how the market pattern of this product will change in the future
.
.
It is worth mentioning that Milrinone injection is in the list of the seventh batch of planned centralized procurement.
Minet will continue to pay attention to how the market pattern of this product will change in the future
.
Source: CDE official website, Minet database
A few days ago, the CDE official website showed that Hunan Hengsheng Pharmaceutical was accepted for its milrinone injection, which was reported to be a generic type 3 product
.
According to data from Minet.
com, the sales of milrinone injection in public medical institutions in China will exceed 900 million yuan in 2020, with a year-on-year increase of 0.
77% in the first half of 2021
.
This product has 15 companies with production approvals, of which 8 have been reviewed
.
Four companies including Sichuan Huiyu Pharmaceutical Co.
, Ltd.
and China Resources Sanjiu (Ya'an) Pharmaceutical Co.
, Ltd.
are under review for production under the new classification, and they will be deemed to have been reviewed after approval
.
.
According to data from Minet.
com, the sales of milrinone injection in public medical institutions in China will exceed 900 million yuan in 2020, with a year-on-year increase of 0.
77% in the first half of 2021
.
This product has 15 companies with production approvals, of which 8 have been reviewed
.
Four companies including Sichuan Huiyu Pharmaceutical Co.
, Ltd.
and China Resources Sanjiu (Ya'an) Pharmaceutical Co.
, Ltd.
are under review for production under the new classification, and they will be deemed to have been reviewed after approval
.
Milrinone injection was developed by Sanofi-Aventis.
It is a phosphodiesterase inhibitor class of cardiotonic drugs.
It has the effect of dilating vascular smooth muscle, reducing the load on the heart and improving blood supply to the kidneys and muscles.
, clinically used for short-term intravenous therapy in patients with acute decompensated heart failure
.
It is a phosphodiesterase inhibitor class of cardiotonic drugs.
It has the effect of dilating vascular smooth muscle, reducing the load on the heart and improving blood supply to the kidneys and muscles.
, clinically used for short-term intravenous therapy in patients with acute decompensated heart failure
.
According to data from Minet.
com, in 2020, the sales of terminal milrinone injection in China's urban public medical care, county-level public hospitals , urban community centers and township health centers (referred to as Chinese public medical institutions) will exceed 900 million yuan, and the first half of 2021 will increase year-on-year.
0.
77%
.
com, in 2020, the sales of terminal milrinone injection in China's urban public medical care, county-level public hospitals , urban community centers and township health centers (referred to as Chinese public medical institutions) will exceed 900 million yuan, and the first half of 2021 will increase year-on-year.
0.
77%
.
Review of Milrinone Injection
Source: One-click retrieval from Minet
Milrinone injection has 15 companies with production approvals, of which 8 have been reviewed.
Over-evaluation, Nanjing Jianyou Biochemical Pharmaceutical and Shanghai Xudong Haipu Pharmaceutical Co.
, Ltd.
were approved for production of 4 types of imitations, which are regarded as over-evaluation
.
Over-evaluation, Nanjing Jianyou Biochemical Pharmaceutical and Shanghai Xudong Haipu Pharmaceutical Co.
, Ltd.
were approved for production of 4 types of imitations, which are regarded as over-evaluation
.
Milrinone injection is under review
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
In addition, four pharmaceutical companies, including Sichuan Huiyu Pharmaceutical and China Resources Sanjiu (Ya'an) Pharmaceutical, are under review for production under the new classification, and will be deemed to have been reviewed after approval
.
It is worth mentioning that Milrinone injection is in the list of the seventh batch of planned centralized procurement.
Minet will continue to pay attention to how the market pattern of this product will change in the future
.
.
It is worth mentioning that Milrinone injection is in the list of the seventh batch of planned centralized procurement.
Minet will continue to pay attention to how the market pattern of this product will change in the future
.
Source: CDE official website, Minet database
A few days ago, the CDE official website showed that Hunan Hengsheng Pharmaceutical was accepted for its milrinone injection, which was reported to be a generic type 3 product
.
According to data from Minet.
com, the sales of milrinone injection in public medical institutions in China will exceed 900 million yuan in 2020, with a year-on-year increase of 0.
77% in the first half of 2021
.
This product has 15 companies with production approvals, of which 8 have been reviewed
.
Four companies including Sichuan Huiyu Pharmaceutical Co.
, Ltd.
and China Resources Sanjiu (Ya'an) Pharmaceutical Co.
, Ltd.
are under review for production under the new classification, and they will be deemed to have been reviewed after approval
.
.
According to data from Minet.
com, the sales of milrinone injection in public medical institutions in China will exceed 900 million yuan in 2020, with a year-on-year increase of 0.
77% in the first half of 2021
.
This product has 15 companies with production approvals, of which 8 have been reviewed
.
Four companies including Sichuan Huiyu Pharmaceutical Co.
, Ltd.
and China Resources Sanjiu (Ya'an) Pharmaceutical Co.
, Ltd.
are under review for production under the new classification, and they will be deemed to have been reviewed after approval
.
Milrinone injection was developed by Sanofi-Aventis.
It is a phosphodiesterase inhibitor class of cardiotonic drugs.
It has the effect of dilating vascular smooth muscle, reducing the load on the heart and improving blood supply to the kidneys and muscles.
, clinically used for short-term intravenous therapy in patients with acute decompensated heart failure
.
heart heartIt is a phosphodiesterase inhibitor class of cardiotonic drugs.
It has the effect of dilating vascular smooth muscle, reducing the load on the heart and improving blood supply to the kidneys and muscles.
, clinically used for short-term intravenous therapy in patients with acute decompensated heart failure
.
According to data from Minet.
com, in 2020, the sales of terminal milrinone injection in China's urban public medical care, county-level public hospitals , urban community centers and township health centers (referred to as Chinese public medical institutions) will exceed 900 million yuan, and the first half of 2021 will increase year-on-year.
0.
77%
.
hospital hospitalcom, in 2020, the sales of terminal milrinone injection in China's urban public medical care, county-level public hospitals , urban community centers and township health centers (referred to as Chinese public medical institutions) will exceed 900 million yuan, and the first half of 2021 will increase year-on-year.
0.
77%
.
Review of Milrinone Injection
Source: One-click retrieval from Minet
Milrinone injection has 15 companies with production approvals, of which 8 have been reviewed.
Over-evaluation, Nanjing Jianyou Biochemical Pharmaceutical and Shanghai Xudong Haipu Pharmaceutical Co.
, Ltd.
were approved for production of 4 types of imitations, which are regarded as over-evaluation
.
enterprise enterpriseOver-evaluation, Nanjing Jianyou Biochemical Pharmaceutical and Shanghai Xudong Haipu Pharmaceutical Co.
, Ltd.
were approved for production of 4 types of imitations, which are regarded as over-evaluation
.
Milrinone injection is under review
Source: MED2.
0 China Drug Evaluation Database
0 China Drug Evaluation Database
In addition, four pharmaceutical companies, including Sichuan Huiyu Pharmaceutical and China Resources Sanjiu (Ya'an) Pharmaceutical, are under review for production under the new classification, and will be deemed to have been reviewed after approval
.
It is worth mentioning that Milrinone injection is in the list of the seventh batch of planned centralized procurement.
Minet will continue to pay attention to how the market pattern of this product will change in the future
.
.
It is worth mentioning that Milrinone injection is in the list of the seventh batch of planned centralized procurement.
Minet will continue to pay attention to how the market pattern of this product will change in the future
.
Source: CDE official website, Minet database
Source: CDE official website, Minet database 
